Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HS-20118 Under Different Dosing Conditions in Healthy Participants
NCT07896915Phase 1Active, not recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HS-20118 in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Started Aug 2026; status: active, not recruiting.
02
Drugs
HS-20118
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07896915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896915.